Latest news with #BlueJetHealthcare
Business Standard
5 hours ago
- Business
- Business Standard
Blue Jet Healthcare hits the floor as Q1 PAT tumbles 17% QoQ to Rs 91 cr
Blue Jet Healthcare hit a lower circuit of 10% at Rs 906.15 after the company's standalone net profit fell 17.19% to Rs 91.17 crore despite 4.2% jump in revenue from operations to Rs 354.75 crore in Q1 FY26 over Q4 FY25. On a year on year basis, the companys net profit and revenue jumped 141.38% and 117.79%, respectively in Q1 FY26. During the quarter, profit before tax (PBT) stood at Rs 122.86 crore, declining 16.54% quarter-on-quarter but rising 148.4% year-on-year. EBITDA stood at 121.0 crore in Q1 FY26, down 13.57% QoQ and up 173.14% YoY. EBITDA margin was at 34.1% in Q1 FY26 as against 27.2% in Q1 FY25. Blue Jet Healthcare is a specialty pharmaceutical and healthcare ingredient and intermediate company, operating under a contract development and manufacturing organization (CDMO) business model. The company has specialized chemistry capabilities in contrast media intermediates and high-intensity sweeteners.
&w=3840&q=100)
Business Standard
7 hours ago
- Business
- Business Standard
Blue Jet Healthcare shares drop 10% post Q1 results; details here
Blue Jet Healthcare share price today: Shares of the pharma company, Blue Jet Healthcare, dropped 10 per cent on Tuesday, July 22, 2025, logging an intraday low of ₹906.15 per share. At 2:30 PM, shares of Blue Jet Healthcare were trading at ₹906.15, down by 10 per cent on the BSE. In comparison, Sensex was trading at 82,193.27, down by 7 points. The market capitalisation of the pharma company stood at ₹15,718.57 crore. So far this calendar year, the shares of the company have witnessed a strong surge of 78 per cent. The selloff on the counter came after the company released its earnings for the first quarter of the financial year 2025-2026 (Q1FY26). Blue Jet Healthcare Q1FY26 earnings The company's revenue from operations figure stood at ₹354.8 crore for the quarter ending June 30, 2025, up from ₹162.9 crore in the corresponding quarter of the previous fiscal year. Profit after tax (PAT) also witnessed a healthy rise of 141.3 per cent to ₹91.2 crore in Q1FY26, up from ₹37.8 crore reported in the first quarter of the previous financial year. However, the company's sequential results failed to uplift the investor sentiment. The pharma company's PAT was down by 17.2 per cent on a quarter-on-quarter (Q-o-Q) basis. PAT margins also declined from 32.3 per cent in Q4FY25 to 25.7 per cent during the quarter under review, marking a decline of 664 basis points (bps). "Reduction in Q-o-Q is primarily attributable to a drop in gross margin to 48.4 per cent in Q1 FY26 from 54.7 per cent in Q4 FY25, driven by a shift in product mix and reduced inventory levels, resulting in lower overhead absorption during Q1FY26," the company said in a release. That apart, the company's earnings before interest, taxes, depreciation and amortisation (Ebitda) figure was down by 13.6 per cent to ₹121 crore in Q1FY26, from ₹140 crore recorded in the previous quarter. Ebitda margins also took a hit and dropped by 701 bps to 34.1 per cent for the quarter ending June 30, 2025, from 41.1 per cent recorded in the fourth quarter of the previous financial year. "Looking ahead, we remain confident in our growth strategy, driven by capacity expansions, enhanced R&D capabilities, and a robust pipeline of high-value products. We are committed to delivering long-term value to our stakeholders through consistent performance, innovation, and strategic investments," said Shiven Arora, managing director of Blue Jet Healthcare Ltd. About Blue Jet Healthcare The pharma company was initially incorporated as 'Jet Chemicals Private Ltd.' in Mumbai on December 7, 1968. The name of the company was changed to 'Blue Jet Healthcare Private' on December 30, 2020. It has operations organised into three product categories: contrast media intermediates, high-intensity sweeteners and pharma intermediates and active pharmaceutical ingredients (APIs). Blue Jet Healthcare is involved in the manufacturing of pharma intermediate APIs used in pharmaceutical and healthcare products.
Time of India
7 hours ago
- Business
- Time of India
Blue Jet Healthcare shares crash 10% post Q1 earnings. Here's what triggered the fall
Blue Jet Healthcare shares: The company posted a 4% drop in June quarter revenue, recording ₹355 crore compared to ₹340 crore in the same quarter of the previous financial year. Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads Shares of Blue Jet Healthcare tanked 10% on Tuesday to hit the day's low Rs 90.6.15 on the NSE following the announcement of its Q1 earnings. The company reported a 17% drop in its sequential net profit to Rs 91 crore versus Rs 110 crore reported in company also reported a 4% decline in its June quarter revenues at Rs 355 crore as against Rs 340 crore reported in the corresponding quarter of the last financial selling pressure was seen despite a 141% surge in Blue Jet's profit after tax (PAT) on a year-on-year basis with the company reporting a bottom line of Rs 38 crore in Q1FY25. The topline increased by 118% on the YoY basis versus Rs 163 crore posted in the April-June quarter of FY25. Blue Jet Healthcare shares hit a 52-week high of Rs 1,027.80 on company's PAT decline could be attributed to a double-digit rise in its quarterly expenses on a QoQ and YoY basis. Blue Jet reported expenses of Rs 240 crore in the quarter under review, up 17% from Rs 205 crore in Q4FY25 and 97% from Rs 122 crore in the year-ago period. The expenses were made under the heads like 'Cost of Materials Consumed', 'Employee Benefits Expense', and 'Finance Cost', among other company is engaged in the manufacturing of artificial sweetener, contrast media intermediate, pharma intermediate, and APIs used in pharmaceutical and healthcare Jet Healthcare is a smallcap stock with a market capitalization of Rs 15,718.57. The stock has been a multibagger with 116% returns over a 1-year period. This stock has rallied 57% on a year-to-date basis notwithstanding today's sharp is currently trading above its 50-day and 200-day simple moving averages (SMAs) of Rs 884 and Rs 705, respectively, according to Trendlyne. The stock has also displayed high volatility in the past one year with a beta of read: IRFC stock tumbles 35% after 551% 3-year surge. What to do ahead of Q1 results?
Economic Times
7 hours ago
- Business
- Economic Times
Blue Jet Healthcare shares crash 10% post Q1 earnings. Here's what triggered the fall
Live Events (You can now subscribe to our (You can now subscribe to our ETMarkets WhatsApp channel Shares of Blue Jet Healthcare tanked 10% on Tuesday to hit the day's low Rs 90.6.15 on the NSE following the announcement of its Q1 earnings. The company reported a 17% drop in its sequential net profit to Rs 91 crore versus Rs 110 crore reported in company also reported a 4% decline in its June quarter revenues at Rs 355 crore as against Rs 340 crore reported in the corresponding quarter of the last financial selling pressure was seen despite a 141% surge in Blue Jet's profit after tax (PAT) on a year-on-year basis with the company reporting a bottom line of Rs 38 crore in Q1FY25. The topline increased by 118% on the YoY basis versus Rs 163 crore posted in the April-June quarter of FY25. Blue Jet Healthcare shares hit a 52-week high of Rs 1,027.80 on company's PAT decline could be attributed to a double-digit rise in its quarterly expenses on a QoQ and YoY basis. Blue Jet reported expenses of Rs 240 crore in the quarter under review, up 17% from Rs 205 crore in Q4FY25 and 97% from Rs 122 crore in the year-ago period. The expenses were made under the heads like 'Cost of Materials Consumed', 'Employee Benefits Expense', and 'Finance Cost', among other company is engaged in the manufacturing of artificial sweetener, contrast media intermediate, pharma intermediate, and APIs used in pharmaceutical and healthcare Jet Healthcare is a smallcap stock with a market capitalization of Rs 15,718.57. The stock has been a multibagger with 116% returns over a 1-year period. This stock has rallied 57% on a year-to-date basis notwithstanding today's sharp is currently trading above its 50-day and 200-day simple moving averages (SMAs) of Rs 884 and Rs 705, respectively, according to Trendlyne. The stock has also displayed high volatility in the past one year with a beta of read: IRFC stock tumbles 35% after 551% 3-year surge. What to do ahead of Q1 results?
Business Standard
8 hours ago
- Business
- Business Standard
Blue Jet Healthcare standalone net profit rises 141.32% in the June 2025 quarter
Sales rise 117.78% to Rs 354.76 croreNet profit of Blue Jet Healthcare rose 141.32% to Rs 91.17 crore in the quarter ended June 2025 as against Rs 37.78 crore during the previous quarter ended June 2024. Sales rose 117.78% to Rs 354.76 crore in the quarter ended June 2025 as against Rs 162.90 crore during the previous quarter ended June EndedJun. 2025Jun. 2024% 118 OPM %34.1127.17 -PBDT128.5652.95 143 PBT122.8649.47 148 NP91.1737.78 141 Powered by Capital Market - Live News
